Novartis Canada

What Novartis Canada does

Novartis Canada (legal entity Novartis Pharmaceuticals Canada Inc.) is the Canadian operating subsidiary of Swiss multinational Novartis AG, headquartered in Dorval, Quebec, and founded in 1996. It manufactures, registers, and distributes innovative prescription pharmaceuticals across oncology, immunology, cardiology, dermatology, rheumatology, nephrology, and hematology, employing 251–500 staff and operating bilingual (English/French) healthcare-professional portals and a medical information hotline to support clinical engagement nationwide.

Its core product portfolio centers on targeted specialty therapies: Kisqali (ribociclib, a CDK4/6 inhibitor for HR+/HER2− breast cancer), Scemblix (asciminib for chronic myeloid leukemia), Cosentyx (secukinumab, an IL-17A inhibitor for hidradenitis suppurativa, psoriasis, psoriatic arthritis, and ankylosing spondylitis), and the radioligand therapy franchise comprising Pluvicto (lutetium 177Lu vipivotide tetraxetan for PSMA-positive metastatic castration-resistant prostate cancer) and Lutathera ([177Lu]Lu-DOTA-TATE for somatostatin-receptor-positive neuroendocrine tumors). Pluvicto received Health Canada approval in August 2022 as the first targeted radioligand therapy of its kind and is delivered through specialized hospital and retail pharmacy channels. The company also runs the Novartis Pro Portal, a digital HCP education platform offering 200+ hours of microlearning content from 50+ Canadian experts across five therapeutic areas.

Revenue is generated through prescription pharmaceutical sales reimbursed primarily via Canadian public payers: pricing is negotiated centrally through the pan-Canadian Pharmaceutical Alliance (pCPA) and implemented provincially, with Ontario's FAST program now accelerating access to breakthrough cancer therapies. As of mid-2025, Pluvicto was publicly reimbursed in seven provinces (Quebec, Ontario, Alberta, British Columbia, Nova Scotia, Saskatchewan, Newfoundland and Labrador), and Cosentyx for hidradenitis suppurativa achieved first-provincial listing in Quebec. The company supplements its commercial operations with two grant programs: NOYCIA (established 2004, over $1.1 million cumulative, $50,000 CAD awarded in 2026 to ten early-career oncology researchers who present at ASCO) and the Health Equity Initiative (over $560,000 awarded in 2025 to organizations addressing systemic health disparities, with the Federal Health Minister in attendance). Leadership transitioned in December 2025 with Dimitri Gitas appointed Country President.

Name

Novartis Canada

Legal name

Novartis Pharmaceuticals Canada Inc.

Website

https://novartis.ca

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

251–500 employees

Short description

Novartis Canada (Novartis Pharmaceuticals Canada Inc.) is the Canadian subsidiary of Novartis AG, selling innovative specialty pharmaceuticals — Kisqali, Scemblix, Cosentyx, Pluvicto, and Lutathera — across oncology, immunology, and rare diseases, reimbursed through provincial drug programs and pCPA negotiations, and serving Canadian healthcare professionals, patients, and public payers.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industry

Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Prescription pharmaceuticals
• Oncology medicines
• Radioligand therapy
• Immunology treatments
• Targeted cancer therapies

Headquarters

HQ city

Dorval

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the sale of prescription pharmaceutical products including Kisqali, Scemblix, Cosentyx, Pluvicto, and other branded medications. Products are distributed through public reimbursement channels (provincial drug programs) and potentially private insurance.
2. Public Reimbursement (Government Payer): Revenue from public drug plans including provincial reimbursement through pCPA negotiations, Ontario's FAST program, and Quebec's public drug program.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Novartis Canada develops, manufactures, and distributes innovative prescription pharmaceutical medicines across oncology, immunology, cardiology, dermatology, rheumatology, nephrology, and hematology. The portfolio includes targeted cancer therapies (Kisqali, Scemblix), radioligand therapies (Pluvicto, Lutathera), and IL-17A inhibitor Cosentyx, distributed primarily through provincial public drug programs and hospital/retail pharmacies under negotiated reimbursement.

Product overview

Novartis Canada operates as a diversified pharmaceutical company offering a portfolio of innovative medicines and digital health solutions. The core product portfolio includes targeted cancer therapies such as Kisqali® (ribociclib) for breast cancer, Scemblix® for chronic myeloid leukemia, Pluvicto® and Lutathera® as radioligand therapies for prostate cancer and neuroendocrine tumors respectively, and Cosentyx® (secukinumab) for inflammatory conditions. Supporting the product portfolio is the Novartis Pro Portal, a digital platform providing healthcare professionals with medical resources, clinical data, and product information. The company also administers grant programs including NOYCIA for oncology researchers and the Health Equity Initiative, reflecting its commitment to advancing cancer research and addressing health disparities in Canada.

Differentiator

Problem solved

Functional benefit

Products and services

• Kisqali (ribociclib tablets) CDK4/6 inhibitor approved for treating hormone receptor-positive, HER2-negative early and metastatic breast cancer, demonstrating 28% reduction in recurrence risk for early-stage patients at high risk of recurrence.
• Scemblix Breakthrough cancer therapy for chronic myeloid leukemia (CML), prioritized under Ontario's FAST program for expedited patient access.
• Cosentyx (secukinumab) IL-17A inhibitor for treating moderate to severe hidradenitis suppurativa (HS), psoriasis, psoriatic arthritis, and ankylosing spondylitis, publicly reimbursed across Canadian provinces.
• Pluvicto (lutetium 177Lu vipivotide tetraxetan) Targeted radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer, the first of its kind approved by Health Canada (August 2022), now publicly funded in seven provinces.
• Lutathera ([177Lu]Lu-DOTA-TATE) Approved radioligand therapy agent for advanced somatostatin receptor-positive neuroendocrine tumors.

Quantifiable outcome

• 28% reduction in recurrence risk demonstrated in clinical trials for Kisqali
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Six partnerships are on record, tiered core and strategic.

• American Society of Clinical Oncology (ASCO)coreStrategic or Co-development Partner · 30 March 2026NOYCIA winners present their research work at the ASCO Annual Meeting in Chicago on May 31, 2026, providing visibility for early-career Canadian oncology researchers.
• American Society for Radiation Oncology (ASTRO)strategicGTM or Marketing Partner · 30 January 2026ASTRO launched National Authorized User Training Centers program supported by educational grant from Novartis Pharmaceuticals Corp to expand the number of physicians certified to deliver radiopharmaceutical therapy.
• Ontario Ministry of HealthcoreStrategic or Co-development Partner · 10 December 2025Ontario's new FAST program prioritizes Scemblix for public reimbursement, aiming to reduce wait times and improve treatment accessibility for patients with chronic myeloid leukemia.
• pan-Canadian Pharmaceutical Alliance (pCPA)coreStrategic or Co-development Partner · 1 December 2025Novartis Canada concluded negotiations with pCPA to secure public reimbursement of Cosentyx for hidradenitis suppurativa and continues collaboration with provincial public drug programs for timely access to innovative therapies nationwide.
• Health Equity Initiative WinnerscoreOthers · 27 November 2025Three Canadian organizations received over $560,000 in grants to support projects addressing systemic health disparities in Canada. Federal Health Minister the Honourable Marjorie Michel attended the Montreal ceremony.
• Quebec Ministry of HealthcoreStrategic or Co-development Partner · 2 July 2025Quebec became the first province to list Pluvicto for public reimbursement, marking a significant milestone for radioligand therapy access in Canada. Pluvicto is now publicly funded in seven provinces.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Merck Canada: Canadian subsidiary of Merck (MSD), anchored by Keytruda in oncology — overlapping prescriber base with Kisqali, Scemblix, and Pluvicto — and competing for similar provincial reimbursement listings and FAST-program priority.
• Pfizer Canada: Canadian operations of Pfizer with a comparable diversified branded pharmaceutical portfolio spanning oncology, inflammation/immunology, and rare diseases — overlapping prescriber segments and similar pCPA pathway.
• Johnson & Johnson Innovative Medicine Canada: Canadian innovative-medicines arm of J&J, with oncology (Darzalex, Erleada, Imbruvica), immunology, and pulmonary hypertension franchises — directly competing for the same specialist prescriber base and payer budgets.
• Bayer Canada: Canadian subsidiary of Bayer, with overlapping oncology portfolio including Xofigo (radium-223) — a radiopharmaceutical therapeutic that puts Bayer in direct competition with Pluvicto and Lutathera on modality and channel.
• Bristol-Myers Squibb Canada: Canadian operations of BMS with strong oncology and hematology franchise (Opdivo, Reblozyl, Pomalyst), overlapping with Scemblix in hematology and Kisqali in breast cancer competitive sets.
• Eli Lilly Canada: Canadian subsidiary of Eli Lilly, direct competitor through Verzenio (abemaciclib) in the CDK4/6 inhibitor space where Kisqali is a flagship product, plus growing oncology and immunology portfolio.
• Roche Canada: Canadian operations of Roche, also anchored by oncology (Tecentriq, Polivy, Hemlibra, Phesgo) and competing biologics, with similar pCPA-led reimbursement model and bilingual HCP engagement.
• AstraZeneca Canada: Canadian subsidiary of AstraZeneca, with overlapping oncology footprint (Tagrisso, Imfinzi, Enhertu) and emerging radioligand therapy capability following the Fusion Pharma acquisition — a direct competitive vector against Pluvicto and Lutathera.
• Sanofi Canada: Canadian operations of Sanofi with immunology focus (Dupixent) — a direct competitor to Cosentyx in dermatology and rheumatology — plus oncology and rare disease assets that overlap with Novartis Canada's broader portfolio.

Broad incumbents

• GSK Canada: Canadian arm of GSK with broad pharma portfolio across specialty (Blenrep, Jemperli) and immunology (Benlysta) — overlapping but less oncology-heavy than Novartis Canada, making it a broader-mix competitor rather than head-to-head in core oncology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/novartis-canada
• Xx.com/novartiscanada
• Facebookfacebook.com/novartis

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novartis Canada